scispace - formally typeset
N

N. C. Gey van Pittius

Researcher at Stellenbosch University

Publications -  22
Citations -  1736

N. C. Gey van Pittius is an academic researcher from Stellenbosch University. The author has contributed to research in topics: Mycobacterium tuberculosis & Drug resistance. The author has an hindex of 18, co-authored 22 publications receiving 1606 citations. Previous affiliations of N. C. Gey van Pittius include DST Systems & University of Cape Town.

Papers
More filters
Journal Article

Differentiation of Mycobacterium tuberculosis complex by PCR amplification of genomic regions of difference.

TL;DR: A two-step, multiplex polymerase chain reaction (PCR) method based on genomic regions of difference allowed for rapid differentiation of members of the Mycobacterium tuberculosis complex, making it suitable for routine laboratories and surveillance purposes.
Journal ArticleDOI

A balancing act: efflux/influx in mycobacterial drug resistance.

TL;DR: The tubercle bacillus has become a central player in the epidemiology of diarrheal disease and its role in this disease has become increasingly important in the management of infectious disease outbreaks.
Journal ArticleDOI

Mycobacterium tuberculosis Beijing genotype: a template for success.

TL;DR: The evidence of hypervirulence of the Beijing genotype as well as other Beijing-associated phenotypic characteristics such as alternate host immune modulation, clinical and pathological features, drug resistance, resistance to BCG vaccination and other epidemiological features are reviewed to enhance the understanding of the contribution of pathogenic factors.
Journal ArticleDOI

Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis

TL;DR: The elements that might influence the mycobacterial mutation rate in vivo are considered and the potential roles of constitutive and transient mutator states in the generation of drug resistance mutations are evaluated.
Journal ArticleDOI

The Diagnostic Performance of the GenoType MTBDRplus Version 2 Line Probe Assay Is Equivalent to That of the Xpert MTB/RIF Assay

TL;DR: The detection of M. tuberculosis in culture-negative specimens confirmed that molecular assays should not be used for treatment monitoring, and the GenoType MTBDRplus (v2.0) assay will complement the Xpert MTB/RIF screening assay by validating rifampin susceptibility and providing information on isoniazid susceptibility.